missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ IL-32 Monoclonal Antibody (373802)
Rat Monoclonal Antibody
Brand: Invitrogen™ MA561249
This item is not returnable.
View return policy
Description
Reconstitute with sterile PBS to a final concentration of 0.5 mg/mL.
Interleukin-32 (IL-32) was initially identified as a transcript (NK4) that is selectively expressed in lymphocytes and NK cells and whose expression is increased following activation by IL-2. It was later re-isolated from an IL-18-treated lung carcinoma cell line and re-named IL-32. IL-32 is unusual in that it does not share sequence homology with known cytokine families and is highly expressed in immune tissues, existing in at least four differentially spliced isoforms. Because treatment of human monocytic and mouse macrophage cells with IL-32 induces several proinflammatory cytokines such as TNF-a, IL-8 and MIP-2, and because it is also induced in human peripheral lymphocyte cells after mitogen stimulation and in epithelial cells by IFN-gamma, it has been suggested that IL-32 may play a role in autoimmune and inflammatory diseases such as rheumatoid arthritis.
Specifications
| IL-32 | |
| Monoclonal | |
| 0.5 mg/mL | |
| PBS with trehalose and no preservative | |
| P24001 | |
| IL32 | |
| E. coli-derived recombinant human IL-32 alpha , Phe3-Lys131. | |
| 100 μg | |
| Primary | |
| Human | |
| Antibody | |
| IgG2a |
| Western Blot, Immunocytochemistry | |
| 373802 | |
| Unconjugated | |
| IL32 | |
| IL32; IL-32; IL-32alpha; IL-32beta; IL-32delta; IL-32gamma; ILN; Interleukin; interleukin 32; interleukin-32; interleukin-32 eta; interleukin-32 small; interleukin-32 theta; natural killer cell transcript 4; natural killer cells protein 4; NK4; TAIF; TAIFa; TAIFb; TAIFc; TAIFd; Tumor necrosis factor alpha-inducing factor | |
| Rat | |
| Protein A/G | |
| RUO | |
| 9235 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction